Suggested remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for the adjuvant treatment of muscle-invasive urothelial cancer with high-risk of recurrence following surgical resection.
 
Status In progress
Process STA 2018
ID number 2694

Provisional Schedule

Committee meeting 10 March 2022
Expected publication 25 May 2022

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb (Nivolumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Fight Bladder Cancer
Professional groups Association of Cancer Physicians
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord (cisplatin, carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Consilient (carboplatin) (confidentiality agreement not signed, not participating)
  Hospira (cisplatin, carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Sandoz (cisplatin) (confidentiality agreement not signed, not participating)
  Sun Pharma (gemcitabine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
16 February 2021 Invitation to participate
01 October 2020 - 29 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
31 July 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance